Addressing the challenge of rapid drug metabolite identification using Cyclic Ion Mobility Mass Spectrometry

Significance of the topic

Rapid and reliable characterization of drug metabolites is a cornerstone of ADME profiling in drug discovery. Early-stage in vitro assays must balance speed and throughput against the ability to resolve structurally related metabolites — particularly isomeric conjugates such as glucuronides that often coelute in shortened LC gradients. Implementing orthogonal gas‑phase separation and signal enhancement strategies can preserve throughput while improving confidence in metabolite identification and quantification.

Objectives and study overview

This study evaluated a combined workflow that pairs fast reversed‑phase UHPLC with Cyclic Ion Mobility Spectrometry–Quadrupole Time‑of‑Flight MS (cyclic IMS‑QToF) to:

• Improve separation and identification of parent drugs and isomeric glucuronide metabolites from human hepatocyte incubations.
• Assess sensitivity gains using Wideband Enhancement (WBE).
• Demonstrate how multi‑pass IMS (extended ion mobility path length) can resolve isomeric metabolites to enable shorter LC gradients and higher sample throughput.

Experimental design and methodology

Incubations and sampling:

• Model compounds: diclofenac and raloxifene at 1 µM each.
• Human hepatocyte incubations at 1 × 10^6 cells/mL with aliquots taken between 0 and 60 minutes. Samples were quenched with methanol, vortexed and centrifuged prior to analysis.

Chromatography and MS acquisition:

• 10‑minute reversed‑phase UHPLC methods coupled to Cyclic IMS–QToF operating in HDMSE (high definition MSE) with positive ESI.
• Ion mobility path length varied between ~1 and 5 meters using multi‑pass experiments to evaluate isomer separation.

Data processing and ID metrics:

• Data acquired with MassLynx and processed using waters_connect and MassMetaSite for metabolite prediction and annotation.
• Predicted collision cross section (CCS) values from waters_connect (CCS on Demand) were used as orthogonal confirmation with an acceptance criterion of ≤5% deviation from predicted values.
• Mass accuracy and fragment ion evidence were also used for metabolite assignment (reported mass errors <2 ppm in processed datasets).

Used instrumentation

The workflow combined the following key instrumentation and software:

• UHPLC system (reversed‑phase, 10 min gradients).
• Cyclic Ion Mobility Spectrometry coupled to Quadrupole Time‑of‑Flight mass spectrometer (cyclic IMS‑QToF) operated in HDMSE mode with +ESI.
• Wideband Enhancement (WBE) ion transmission feature on the MS platform for sensitivity gains.
• Data systems: MassLynx for acquisition; waters_connect (including CCS on Demand) and MassMetaSite for processing and metabolite structure prediction.

Main results and discussion

Metabolite detection and confidence:

• Rapid UHPLC–cyclic IMS–MS resolved and annotated multiple glucuronide metabolites of diclofenac and raloxifene from hepatocyte incubations. Processed results reported mass errors <2 ppm and supporting fragment and CCS information.
• Two putative raloxifene glucuronides were observed at retention times of ~3.55 and 3.82 minutes (60 min timepoint). A diclofenac glucuronide was highlighted at ~4.96 minutes in processed outputs.

Sensitivity improvements with WBE:

• WBE produced approximately a 10‑fold higher response for diclofenac at 0.1 ng/mL compared with WBE disabled, markedly improving limits of detection.
• Calibration data for raloxifene glucuronide standards over 0.01–25 ng/mL showed improved signal‑to‑noise at the lowest level (0.01 ng/mL): S/N = 24.5 with WBE vs 13.3 without. Reported R2 values for the calibration were reported to be slightly below 0.99.

Isomer separation using multi‑pass IMS:

• Extending the IMS path length via multi‑pass experiments increased drift time separation and enabled baseline or improved separation of isomeric glucuronide species (e.g., raloxifene conjugates at different hydroxyl positions), even when using shortened LC gradients.
• This orthogonal separation reduces reliance on long LC gradients to resolve positional isomers and helps deconvolute coeluting species that share the same exact mass and similar fragmentation.

Data handling and workflow readiness:

• Processed outputs from waters_connect and MassMetaSite provided time‑course plotting for monitoring metabolite formation and high‑quality exportable data compatible with downstream third‑party tools.

Key benefits and practical applications

The combined rapid UHPLC + cyclic IMS‑QToF workflow offers several practical advantages for ADME screening labs:

• Higher confidence in metabolite structural assignments by combining accurate mass, fragment ions and CCS as orthogonal metrics.
• Significant sensitivity gains through WBE that lower practical LOD/LOQ and enable quantification at sub‑ng/mL levels.
• Ability to shorten LC gradients while preserving separation of isomeric metabolites via multi‑pass IMS, increasing sample throughput and turnaround time.
• Compatibility with common metabolite‑prediction and reporting software (waters_connect, MassMetaSite) for streamlined processing and reporting.

Future trends and potential uses

Opportunities and likely developments informed by this work include:

• Broader adoption of cyclic IMS and multi‑pass IMS strategies in early ADME workflows to decouple chromatographic runtime from isomer separation requirements.
• Integration of predicted CCS libraries into routine metabolite ID pipelines to automate orthogonal confirmation and prioritize standards confirmation.
• Further optimization of ion‑transmission enhancements like WBE and other hardware/software improvements to push quantification limits for low‑abundance metabolites.
• Application of the approach to other conjugative and oxidative metabolite classes where positional isomerism complicates interpretation (e.g., sulfates, positional hydroxylations).

Conclusions

Combining rapid UHPLC with cyclic IMS‑QToF and WBE provides a practical, workflow‑ready solution to accelerate metabolite profiling without sacrificing structural confidence. Multi‑pass IMS extends gas‑phase separation to resolve isomeric glucuronides that would otherwise coelute in short LC gradients, while WBE markedly improves sensitivity and quantification capability. Together, these elements enable faster ADME screening with higher confidence in metabolite identification and more efficient use of laboratory resources.

References

• Munjoma N., Drouyé F., Plumb R., Marsden‑Edwards E. Addressing the challenge of rapid drug metabolite identification using Cyclic Ion Mobility Mass Spectrometry. Waters Corporation scientific poster. 2026. Poster reference 720009577EN.